PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem
Market characteristics
Market segmentation analysis

PART 04: MARKET SIZING

Market definition
Market sizing 2018
Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition

PART 06: PIPELINE ANALYSIS

PART 07: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product
Comparison by product
VELCADE - Market size and forecast 2018-2023
KYPROLIS - Market size and forecast 2018-2023
NINLARO - Market size and forecast 2018-2023
Other products - Market size and forecast 2018-2023
Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

Market drivers
Market challenges

PART 12: MARKET TRENDS

Expanded application
Strategic alliances
Special drug designations

PART 13: VENDOR LANDSCAPE

Overview
Landscape disruption
Competitive scenario

PART 14: VENDOR ANALYSIS

Vendors covered
Vendor classification
Market positioning of vendors
Allergan Plc
Amgen Inc.
Celgene Corp.
Johnson & Johnson Services Inc.
Takeda Pharmaceutical Co. Ltd.

PART 15: APPENDIX

Research methodology
List of abbreviations
Definition of market positioning of vendors
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global proteasome inhibitors market pipeline: Overview
Exhibit 18: Global proteasome inhibitors market pipeline: Snapshot
Exhibit 19: Product - Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: VELCADE - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: VELCADE - Year-over-year growth 2019-2023 (%)
Exhibit 23: KYPROLIS - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: KYPROLIS - Year-over-year growth 2019-2023 (%)
Exhibit 25: NINLARO - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: NINLARO - Year-over-year growth 2019-2023 (%)
Exhibit 27: Other products - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Other products - Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by product
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: North America - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in North America
Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Europe
Exhibit 39: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in Asia
Exhibit 42: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 43: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 44: Top 3 countries in ROW
Exhibit 45: Key leading countries
Exhibit 46: Market opportunity
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: Allergan Plc - Vendor overview
Exhibit 54: Allergan Plc - Product segments
Exhibit 55: Allergan Plc - Organizational developments
Exhibit 56: Allergan Plc - Geographic focus
Exhibit 57: Allergan Plc - Segment focus
Exhibit 58: Allergan Plc - Key offerings
Exhibit 59: Allergan Plc - Key customers
Exhibit 60: Amgen Inc. - Vendor overview
Exhibit 61: Amgen Inc. - Business segments
Exhibit 62: Amgen Inc. - Organizational developments
Exhibit 63: Amgen Inc. - Geographic focus
Exhibit 64: Amgen Inc. - Key offerings
Exhibit 65: Amgen Inc. - Key customers
Exhibit 66: Celgene Corp. - Vendor overview
Exhibit 67: Celgene Corp. - Business segments
Exhibit 68: Celgene Corp. - Organizational developments
Exhibit 69: Celgene Corp. - Geographic focus
Exhibit 70: Celgene Corp. - Key offerings
Exhibit 71: Celgene Corp. - Key customers
Exhibit 72: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 73: Johnson & Johnson Services Inc. - Business segments
Exhibit 74: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 75: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 76: Johnson & Johnson Services Inc. - Segment focus
Exhibit 77: Johnson & Johnson Services Inc. - Key offerings
Exhibit 78: Johnson & Johnson Services Inc. - Key customers
Exhibit 79: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 80: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 81: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 82: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 83: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 84: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 85: Validation techniques employed for market sizing
Exhibit 86: List of abbreviations
Exhibit 87: Definition of market positioning of vendors

Companies Mentioned

• Allergan Plc
• Amgen Inc.
• Celgene Corp.
• Johnson & Johnson Services Inc.
• Takeda Pharmaceutical Co. Ltd.